“The SCOPE data reported so far are highly encouraging, with SCIB1 immunotherapy showing excellent efficacy and long-term survival benefits that signal a meaningful improvement over standard of care”
RE: The Times article on ASDA continued..17 Mar 2025 08:40
Agreed, very brutal sell off in a very short time frame. It looks like it’s likely headed to 300 -308p near term which should then bounce back quite well.